Medtronic plc acted on the increase in M&A and expansion of its investment ecosystem touted at the J.P. Morgan Healthcare Conference earlier this month with a $90 million infusion into Anteris Technologies Global Corp. The investment had been contingent on a public offering of stock by Anteris, which it completed on Jan. 22. Together, the new funds for the biomimetic heart valve company totalled $320 million.
Samantree secures €20M from the EIB
Samantree Medical SA is the latest med-tech company to secure financing from the European Investment Bank (EIB), highlighting the bank’s commitment to supporting key medical technologies across the continent. The company received a €20 million (US$23.95 million) loan which will go towards accelerating the development and commercialisation of its Histolog Scanner, which allows surgeons and pathologists to visualize large, fresh tissue samples in real-time with high resolution and accuracy.
Zylox-Tonbridge expands to Europe with €18M Optimed buy
Zylox-Tonbridge Medical Technology Co. Ltd. plans to expand globally with M&As, company chairman and CEO Jonathon Zhong Zhao told BioWorld, starting with a stepwise acquisition of Optimed Holding GmbH and its subsidiaries, including Optimed Medizinische Instrumente GmbH. “This is the first step of our international expansion, but it’s not going to be the last,” Zhao said. “With support from professional advisors, we plan on more acquisitions in the future.” Under the terms announced Jan. 16, Hangzhou, Zylox-Tonbridge will acquire from E-Med Solutions GmbH a 49% stake in Optimed at an initial valuation of €18.37 million (CN¥149.41 million). The €18 million is a preliminary evaluation subject to a final audit and could reach up to €23 million.
EU trade groups call for action on third-party litigation funding
Third-party litigation funding (TPLF) has proven highly controversial in the U.S. even as the practice has its defenders, but the controversy has overflown the Atlantic Ocean and is now topical in the EU. Med Tech Europe and several other trade associations have signed onto a document calling for reforms of TPLF, making the case an absence of oversight could add as much as €85 billion annually to the cost of doing business in the EU.
Industry sees overreach in FDA’s QMS draft for premarket filings
The U.S. FDA’s October 2025 draft guidance for quality management system information in premarket filings follows the agency’s overhaul of Part 820 of the Code of Federal Regulations, but industry appears to see the draft guidance as a classic example of unfettered regulatory ambition. Both the Advanced Medical Technology Association and the Medical Device Manufacturers Association voiced concerns that the draft proposes the disclosure of quality system information in premarket filings that is out of bounds with historical practice and which could generate more noise than meaningful information in the affected submission types.
Publisher’s note: Med-tech content will be featured in BioWorld
Beginning Feb. 2, 2026, medical technology news and analysis will be integrated into BioWorld, where curated coverage will continue as part of BioWorld’s core reporting.
This transition reflects how innovation across the life sciences is increasingly interconnected. By featuring med-tech coverage within BioWorld, readers gain a more complete perspective of key developments in medical technologies alongside therapeutics all in one place.
The final edition of BioWorld MedTech will publish on Jan. 30, 2026, introducing a more streamlined and comprehensive experience for readers starting on Monday, Feb. 2, 2026.
All existing BioWorld MedTech subscribers will be automatically transitioned to BioWorld Premium, ensuring continued access to med-tech coverage as part of a broader view of research, clinical development and commercialization.
As BioWorld continues its mission to cut through the noise of the life sciences industry with accuracy, clarity and context, this integration ensures readers are well-positioned to track the connections shaping innovation across the global life sciences ecosystem.
Thank you for being part of the BioWorld MedTech community. We invite you to continue following coverage within BioWorld.